Dr. Saeid Babaei – Chairman
PhD, Immunology, U of Toronto | Executive MBA, University of Toronto
Dr. Babaei has over 20 years of experience in leadership roles in the biopharmaceutical industry. He is currently President, & CEO of AbCelex Technologies with a proprietary antibody-based platform technology for animal health and human diagnostics. Prior to AbCelex, Dr. Babaei has served as Vice President of Business Development at Aptose Biosciences where he played a key role in a broad range of activities including establishing joint ventures, obtaining private financings, investor relations, and business development. He successfully negotiated a partnership deal for Virulizin, a cancer immunotherapy product candidate to Zor Pharmaceuticals, a subsidiary of Zoticon Bioventures. Previously, Dr. Babaei’s served as Director of Corporate Development at Northern Therapeutics Inc, a biopharmaceutical company which develops novel cell and gene therapies, where he was instrumental in launching the ‘first’ cell-based gene therapy clinical trial for patients with pulmonary arterial hypertension. He played key roles in obtaining financings, and in securing a partnership deal with United Therapeutics. Dr. Babaei currently serves as Chairman of the Board for BriaCell Therapeutics, an immuno-oncology biotech focused on late-stage breast cancer.
MR. ISAAC MARESKY – EXECUTIVE DIRECTOR
Mr. Isaac Maresky is a Principal with Sunel Securities investment bank, where he focuses identification and execution of unique and attractive investment opportunities for the firm and its investors. In that regard, Mr. Maresky has visited and assessed assets and investment opportunities in several countries around the globe, and to date has been involved in hundreds of millions of dollars of transactions. Mr. Maresky has worked for the Royal Bank of Canada, as well as for Standard Chartered in its M&A group.
Mr. Gadi Levin – CEO & CFO
BComm | Chartered Accountant | MBA
Mr. Levin is an accountant with clinical-stage biotech experience through another position held as Chief Financial Officer of a breast cancer immunotherapy focused firm.
Mr. Levin Most recently, acted as Chief Financial Officer of Labstyle Innovations Ltd, a biotechnology company focused on diabetes. Mr. Levin served as the Vice President of Finance and Chief Financial Officer for two Israeli investment houses in the fields of private equity, hedge funds and real estate (2008 to 2009 and 2010, respectively). Prior to that, Mr. Levin acted as Financial Consultant to various firms.
Mr. Levin began his career at the former “Big Five” accounting firm Arthur Andersen, where he worked in the Cape Town, London, and Tel Aviv offices for nine years. He holds a Bachelor of Commerce degree in Accounting and Information Systems from the University of the Cape Town, South Africa, and a Post-Grad in Accounting from the University of South Africa. He received his Chartered Accountant designation in South Africa and has an MBA from Bar Ilan University in Israel.
Dr. Benjamin Chen – Director
Cancer Research Fellow, Stanford | PhD, Immunology, U Wisconsin | MSc, Immunology, U Wisconsin | BSc, Bacteriology, U Wisconsin | Inventor on 7 patents, Published 64 times
Dr. Benjamin Chen was a Managing Director at Burrill & Co, a global life sciences merchant bank. Dr. Chen held an R&D leadership role at SyStemix, which was acquired by Novartis. In addition, he was instrumental in Sentinel Biosciences which was acquired by Roche. Dr. Chen obtained his MSc and PhD in Immunology from the University of Wisconsin, and was a Cancer Research Fellow at Stanford.